Bristol-Myers Squibb appoints new senior vice-president

Bristol-Myers Squibb has announced the appointment of Jeremy Levin as senior vice-president of external science, technology and licensing, with Mr Levin reporting to president of research and development and chief scientific officer Elliot Sigal.

Prior to this announcement, Dr Levin was employed by the Novartis Institutes of Biomedical Research as global head of business development.

Before his work at Novartis, Dr Levin held key positions in a number of biotechnology firms, including Cadus Pharmaceutical and Physiome Sciences, in addition to his role as life sciences venture fund managing director.

Dr Sigal said: “I am delighted Jeremy has joined our [research and development] organisation at this critical juncture for Bristol-Myers Squibb, as we look to further build our robust pipeline in areas of significant unmet medical need and to transform our pharmaceutical business for the future.”

He added that Dr Levin’s network across the fields of pharmaceuticals, biotechnology and venture capitalism will aid the firm in its efforts to maintain its leadership in the development of innovative drugs and forming of originative alliances.

In February 2007, Sandra Leung was named as senior vice-president with responsibility for the company’s legal division and legal advisor to its board of directors.